US Federal 2025-2026 Regular Session

US Federal House Bill HB2111

Introduced
 
Introduced
3/14/25  

Caption

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Summary

HB2111 would amend the Federal Food, Drug, and Cosmetic Act to exclude premium cigars from the definition of “tobacco product,” which would remove premium cigars from certain FDA tobacco regulations. The bill defines a premium cigar narrowly, requiring that it be wrapped in whole tobacco leaf, use a 100 percent leaf tobacco binder, contain at least 50 percent long-filler tobacco, be handmade or hand rolled, have no filter or non-tobacco mouthpiece, contain no characterizing flavor other than tobacco, include only tobacco, water, and vegetable gum, and weigh more than 6 pounds per 1,000 units. The bill’s findings argue that premium cigars are a small segment of the market, are mostly sold in age-controlled retail settings, and are used almost exclusively by adults. It cites National Academies research suggesting premium cigar use is limited, less common among youth, and generally lower in frequency and intensity than other cigar use. The findings also reference a federal court decision that, in Congress’s view, supports treating premium cigars differently and leaving any remaining health regulation to the states. If enacted, the bill would change federal law by carving premium cigars out of FDA tobacco-product authority under the FDCA. That would likely reduce or eliminate certain federal product, marketing, and regulatory requirements for qualifying premium cigars, while leaving state and local regulation in place. The bill does not appear to alter state law directly, but it would shift more of the regulatory burden away from the federal level and toward state-level oversight. The available context shows little recorded controversy in committee because there were no transcripts or votes provided, but the bill’s subject matter suggests the main policy divide is between industry relief and public health regulation. Supporters are likely to emphasize the small market share, adult-only consumer base, and family-owned business character of the premium cigar industry. Opponents would likely focus on tobacco-control concerns, the health risks of cigar smoking, and the precedent of exempting a tobacco category from federal oversight.

Impact

The bill would amend 21 U.S.C. 321(rr) in the Federal Food, Drug, and Cosmetic Act to exclude premium cigars from the federal definition of “tobacco product.” As a result, qualifying premium cigars would no longer be subject to the same FDA tobacco-product regulatory framework that applies to other tobacco products under the FDCA. The bill does not create new state requirements or preempt state regulation; instead, it leaves room for state and local governments to regulate premium cigars, consistent with the bill’s findings.

Sentiment

No committee transcript or vote record is available, so there is no documented floor or committee sentiment in the provided materials. The bill’s findings and sponsor lineup suggest a generally supportive framing around protecting a niche, small-business tobacco sector from federal regulation, while the absence of recorded opposition in the provided context limits any firm conclusion. The policy debate implied by the text is likely mixed, with industry and deregulation supporters on one side and tobacco-control/public health advocates on the other.

Contention

The central point of contention is whether premium cigars should be treated differently from other tobacco products for federal regulatory purposes. Supporters are likely to argue that premium cigars are a small, adult-oriented product category sold through age-restricted channels and that the FDA’s rules are overly broad for this market. Critics are likely to argue that premium cigars still pose health risks and should remain within the federal tobacco regulatory regime, especially because the bill would create a categorical exemption rather than a more tailored regulatory approach. Another likely dispute is whether the bill’s narrow definition is sufficiently precise to prevent broader cigar products from being swept into the exemption.

Companion Bills

No companion bills found.

Previously Filed As

US HB1843

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

US SF1388

Certain cigars exemption from the taxes imposed on tobacco products and premium cigars

US HF926

Sales of certain cigars exempted from the excise taxes imposed on tobacco products and premium cigars.

US SB3137

Relating To The Department Of Health's Authority To Regulate Food, Drugs, And Cosmetics.

US HB2317

Relating To The Department Of Health's Authority To Regulate Food, Drugs, And Cosmetics.

US SB632

To Amend The Food, Drug, And Cosmetic Act; And To Require Warning Labels For Hair Relaxers That Contain Certain Chemicals.

US HB398

Food, drugs, and cosmetics; authorize production and sale of cottage food items with certain exemptions, requirements, and disclosures

US SB255

To Amend The Definition Of "drug" Within The Food, Drug, And Cosmetic Act; And To Declare An Emergency.

US S02133

Provides that certain persons shall not be deemed a distributor for certain sales of premium cigars; provides that the tax on premium cigars shall be at the rate of seventy-five percent of the wholesale price or fifty cents, whichever is less, and is intended to be imposed only once upon the sale of any premium cigars; defines "premium cigar".

US SF3421

Cosmetics toxics regulations provisions

Similar Bills

US HR198

Providing for the expenses of certain committees of the House of Representatives in the One Hundred Nineteenth Congress.

MN HC1

A house concurrent resolution relating to the regent nomination joint committee.

IL HR0020

HOUSE RULES-AMEND

CA AB1350

Employment Development Department: policies and practices.

NM HJM2

Combine Standing & Interim Committees

MN HC2

A House concurrent resolution relating to the adjournment of the House of Representatives and Senate until 2026.

CA SB829

California Institute for Scientific Research: CalRx Initiative: vaccines.

AR HB1573

To Reorganize The Standing Committees And The Subject Matter Interim Committees Of The House Of Representatives.